The buy ratings keep piling in for ResMed. The post Citi slaps buy rating on ResMed shares appeared first on The Motley Fool ...

ResMed has grown into a company that specialises in non-invasive technology solutions that improve sleep health worldwide.

ResMed makes continuous positive airway pressure machines (CPAP), which offer a non-invasive treatment option for sleep apnea characterized by brief interruptions of breathing during sleep.

Its core business includes the development of devices for sleep apnea -- such as CPAP and APAP machines -- and digital health solutions. Key success factors for ResMed include maintaining ...

ResMed reported $1.28 billion in revenue and ... This is likely to positively impact the demand for CPAP machines. Research indicates that one in three Americans uses an electric sleep tracker ...

Analysts project continued growth for ResMed, with FY25 revenue estimated at $5.14 billion and FY26 revenue at $5.53 billion. Corresponding EPS projections stand at $9.43 for FY25 and $10.51 for FY26 ...